Keyword: Catalent

News

Catalent Buying BMS Site in Italy

24.06.2019 - Continuing a buying spree that has added adding biologics and gene therapy capabilities to its manufacturing repertoire, California-based US drug developer Catalent is buying a...

News

Catalent Expands German Softgel Output

26.04.2019 - US drug developer Catalent has announced plans to expand its integrated turnkey softgel capabilities at Eberbach, Germany, at a cost of $14 million up to 2020. The expansion...

News

Catalent to Buy Paragon Bioservices for $1.2 Billion

16.04.2019 - As the series of multi-billion-dollar buyouts among Contract Development Manufacturing Organizations (CDMOs) continues, US drug developer Catalent has announced it will acquire...

News

Catalent Appoints Kay Schmidt as Senior Vice President of Technical Operations

25.02.2019 - Catalent appointed Kay Schmidt as senior vice president, Technical Operations. In this new role, Schmidt will report to Alessandro Maselli, who earlier this month was appointed as...

News

Catalent Invests $200 Million on Biologics

10.01.2019 - US-based Catalent is investing $200 million in its biologics business to expand drug substance manufacturing capacity and fill/finish capabilities at its sites in Madison...

Plant Construction & Process Technology

M&A in Pharma and CRO/CMO Industry

19.09.2018 - Recently, the pharmaceutical contract development and manufacturing organization (CDMO) industry has been extremely active in M&A, as is the pharma and generics industry itself...

Plant Construction & Process Technology

A Wide Spectrum of Contract Services

19.09.2018 - With its pending $425-million acquisition of Halo Pharmaceuticals, Cambrex joins other contract providers that have used acquisitions in recent years to build end-to-to end service...

News

Catalent Pays $133 Million for Juniper Pharmaceuticals

04.07.2018 - US pharma Catalent has agreed to buy Juniper Pharmaceuticals, including UK-based Juniper Pharma Services, for $133 million, boosting its drug development activities. The addition...